Picato (ingenol mebutate)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- ingenol mebutate
- Company
- LEO Laboratories Ltd.
- Status
- Withdrawn
- Therapeutic area
- Keratosis, Actinic
- EU approval
- Thu 15 Nov 2012
- Designations
- Additional monitoring
- Application
- EMEA/H/C/002275
- ATC
- D06BX02
- Official record
- www.ema.europa.eu
Indication
Picato is indicated for the cutaneous treatment of non?hyperkeratotic, non?hypertrophic actinic keratosis in adults.
Regulatory milestones
No milestones recorded in the last year.
Follow Picato
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.